Natus Medical (BABY) Stock Rating Upgraded by Zacks Investment Research
Zacks Investment Research upgraded shares of Natus Medical (NASDAQ:BABY) from a sell rating to a hold rating in a report issued on Friday.
According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. “
Several other equities research analysts also recently commented on the company. BidaskClub raised Natus Medical from a hold rating to a buy rating in a report on Thursday, August 2nd. ValuEngine raised Natus Medical from a sell rating to a hold rating in a report on Saturday, July 28th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has an average rating of Buy and an average target price of $44.33.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings results on Wednesday, July 25th. The medical equipment provider reported $0.35 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.09. The company had revenue of $130.70 million for the quarter, compared to analysts’ expectations of $130.60 million. Natus Medical had a positive return on equity of 11.18% and a negative net margin of 4.16%. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.34 earnings per share. equities analysts anticipate that Natus Medical will post 1.55 earnings per share for the current fiscal year.
In other Natus Medical news, Director Robert A. Gunst sold 9,100 shares of the business’s stock in a transaction on Friday, July 27th. The stock was sold at an average price of $34.11, for a total value of $310,401.00. Following the sale, the director now directly owns 54,982 shares of the company’s stock, valued at $1,875,436.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ken Ludlum sold 8,000 shares of the business’s stock in a transaction on Thursday, August 2nd. The stock was sold at an average price of $36.89, for a total value of $295,120.00. Following the completion of the sale, the director now directly owns 98,957 shares in the company, valued at $3,650,523.73. The disclosure for this sale can be found here. Insiders sold 37,940 shares of company stock worth $1,337,835 over the last three months. Corporate insiders own 5.50% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in BABY. SG Americas Securities LLC bought a new position in shares of Natus Medical during the first quarter valued at $124,000. US Bancorp DE lifted its holdings in shares of Natus Medical by 81.2% during the first quarter. US Bancorp DE now owns 4,742 shares of the medical equipment provider’s stock valued at $159,000 after purchasing an additional 2,125 shares in the last quarter. Sei Investments Co. lifted its holdings in shares of Natus Medical by 46.3% during the second quarter. Sei Investments Co. now owns 4,669 shares of the medical equipment provider’s stock valued at $161,000 after purchasing an additional 1,478 shares in the last quarter. Xact Kapitalforvaltning AB bought a new position in shares of Natus Medical during the second quarter valued at $201,000. Finally, Profund Advisors LLC bought a new position in shares of Natus Medical during the first quarter valued at $218,000. 88.64% of the stock is currently owned by institutional investors and hedge funds.
About Natus Medical
Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Further Reading: What do I need to know about analyst ratings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.